These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7507625)

  • 21. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccine protection of rhesus macaques against simian immunodeficiency virus infection.
    Carlson JR; McGraw TP; Keddie E; Yee JL; Rosenthal A; Langlois AJ; Dickover R; Donovan R; Luciw PA; Jennings MB
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1239-46. PubMed ID: 2078406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.
    Kilgore KM; Murphy MK; Burton SL; Wetzel KS; Smith SA; Xiao P; Reddy S; Francella N; Sodora DL; Silvestri G; Cole KS; Villinger F; Robinson JE; Pulendran B; Hunter E; Collman RG; Amara RR; Derdeyn CA
    J Virol; 2015 Aug; 89(16):8130-51. PubMed ID: 26018167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques.
    Mitchell WM; Torres J; Johnson PR; Hirsch V; Yilma T; Gardner MB; Robinson WE
    AIDS; 1995 Jan; 9(1):27-34. PubMed ID: 7893438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.
    Robert-Guroff M; Aldrich K; Muldoon R; Stern TL; Bansal GP; Matthews TJ; Markham PD; Gallo RC; Franchini G
    J Virol; 1992 Jun; 66(6):3602-8. PubMed ID: 1374810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The appearance of escape variants in vivo does not account for the failure of recombinant envelope vaccines to protect against simian immunodeficiency virus.
    Almond N; Jenkins A; Jones S; Arnold C; Silvera P; Kent K; Mills KHG; Stott EJ
    J Gen Virol; 1999 Sep; 80 ( Pt 9)():2375-2382. PubMed ID: 10501490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of serum antibody reactivities to a conformational and to linear antigenic sites in the external envelope glycoprotein of simian immunodeficiency virus (SIVmac) induced by infection and vaccination.
    McBride BW; Corthals G; Rud E; Kent K; Webster S; Cook N; Cranage MP
    J Gen Virol; 1993 Jun; 74 ( Pt 6)():1033-41. PubMed ID: 7685372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.
    Burton SL; Kilgore KM; Smith SA; Reddy S; Hunter E; Robinson HL; Silvestri G; Amara RR; Derdeyn CA
    Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10780-5. PubMed ID: 26261312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities.
    Johnson WE; Sanford H; Schwall L; Burton DR; Parren PW; Robinson JE; Desrosiers RC
    J Virol; 2003 Sep; 77(18):9993-10003. PubMed ID: 12941910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypervariable epitope constructs representing variability in envelope glycoprotein of SIV induce a broad humoral immune response in rabbits and rhesus macaques.
    Meyer D; Anderson DE; Gardner MB; Torres JV
    AIDS Res Hum Retroviruses; 1998 Jun; 14(9):751-60. PubMed ID: 9643375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.
    Kumar A; Mukherjee S; Shen J; Buch S; Li Z; Adany I; Liu Z; Zhuge W; Piatak M; Lifson J; McClure H; Narayan O
    Virology; 2002 Sep; 301(2):189-205. PubMed ID: 12359422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope.
    Quesada-Rolander M; Mäkitalo B; Thorstensson R; Zhang YJ; Castaños-Velez E; Biberfeld G; Putkonen P
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):993-9. PubMed ID: 8827215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.
    Means RE; Matthews T; Hoxie JA; Malim MH; Kodama T; Desrosiers RC
    J Virol; 2001 Apr; 75(8):3903-15. PubMed ID: 11264379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of transmission of simian immunodeficiency virus from vaccinated macaques that developed transient virus infection following challenge.
    Shafferman A; Lewis MG; McCutchan FE; Benveniste RE; Jahrling PB; Burke DS; Eddy GA
    Vaccine; 1993; 11(8):848-52. PubMed ID: 8356845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymphocyte-tropic simian immunodeficiency virus causes persistent infection in the brains of rhesus monkeys.
    Stephens EB; Liu ZQ; Zhu GW; Adany I; Joag SV; Foresman L; Berman NE; Narayan O
    Virology; 1995 Nov; 213(2):600-14. PubMed ID: 7491784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maturation of envelope-specific antibody responses to linear determinants in monkeys inoculated with attenuated SIV.
    Cole KS; Paliotti MJ; Murphey-Corb M; Montelaro RC
    J Med Primatol; 2000 Aug; 29(3-4):220-30. PubMed ID: 11085584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein.
    Javaherian K; Langlois AJ; Montefiori DC; Kent KA; Ryan KA; Wyman PD; Stott J; Bolognesi DP; Murphey-Corb M; Larosa GJ
    J Virol; 1994 Apr; 68(4):2624-31. PubMed ID: 7511176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
    Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
    Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A conformational C4 peptide polymer vaccine coupled with live recombinant vector priming is immunogenic but does not protect against rectal SIV challenge.
    Patterson LJ; Robey F; Muck A; Van Remoortere K; Aldrich K; Richardson E; Alvord WG; Markham PD; Cranage M; Robert-Guroff M
    AIDS Res Hum Retroviruses; 2001 Jun; 17(9):837-49. PubMed ID: 11429125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.